California State Teachers Retirement System Buys 36,183 Shares of Xenon Pharmaceuticals Inc. $XENE

Key Points

• California State Teachers Retirement System increased its Xenon Pharmaceuticals stake by 64%, buying 36,183 shares to hold 92,747 shares valued at approximately $5.4 million. Institutional investors collectively own 95.45% of the company.
• Wall Street remains broadly bullish on XENE, with a consensus “Buy” rating and an average price target of $77.20; 16 analysts rate it Buy or Strong Buy, while one rates it Sell.
• Xenon shares opened at $64.55, near the upper half of their $32.78–$72.66 one-year range. The company recently reported a quarterly loss of $1.11 per share, beating analysts’ expected loss of $1.16.

California State Teachers Retirement System increased its stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 64.0% in the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 92,747 shares of the biopharmaceutical company's stock after purchasing an additional 36,183 shares during the quarter. California State Teachers Retirement System owned about 0.10% of Xenon Pharmaceuticals worth $5,393,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in the stock. Kestra Advisory Services LLC purchased a new position in Xenon Pharmaceuticals during the 4th quarter valued at about $33,000. Blue Trust Inc. boosted its position in shares of Xenon Pharmaceuticals by 2,560.7% in the fourth quarter. Blue Trust Inc. now owns 745 shares of the biopharmaceutical company's stock valued at $33,000 after acquiring an additional 717 shares during the period. Danske Bank A S purchased a new position in Xenon Pharmaceuticals during the third quarter valued at approximately $32,000. Caitong International Asset Management Co. Ltd purchased a new position in Xenon Pharmaceuticals during the fourth quarter valued at approximately $43,000. Finally, Rockefeller Capital Management L.P. increased its holdings in Xenon Pharmaceuticals by 450.0% during the 4th quarter. Rockefeller Capital Management L.P. now owns 1,100 shares of the biopharmaceutical company's stock worth $49,000 after acquiring an additional 900 shares during the period. Hedge funds and other institutional investors own 95.45% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on the company. Wells Fargo & Company reiterated an "overweight" rating and issued a $69.00 price objective on shares of Xenon Pharmaceuticals in a research report on Sunday, May 10th. Royal Bank Of Canada boosted their target price on Xenon Pharmaceuticals from $80.00 to $82.00 and gave the stock an "outperform" rating in a research report on Friday, May 8th. Weiss Ratings restated a "sell (d-)" rating on shares of Xenon Pharmaceuticals in a research note on Monday, July 6th. JPMorgan Chase & Co. raised their price target on Xenon Pharmaceuticals from $80.00 to $82.00 and gave the company an "overweight" rating in a report on Wednesday, May 27th. Finally, Needham & Company LLC dropped their price target on Xenon Pharmaceuticals from $80.00 to $78.00 and set a "buy" rating for the company in a research report on Friday, May 8th. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and an average price target of $77.20.

Insider Buying and Selling at Xenon Pharmaceuticals

In other Xenon Pharmaceuticals news, Director Gary Patou sold 1,322 shares of Xenon Pharmaceuticals stock in a transaction on Friday, June 5th. The stock was sold at an average price of $53.14, for a total transaction of $70,251.08. Following the completion of the transaction, the director owned 24,896 shares in the company, valued at approximately $1,322,973.44. The trade was a 5.04% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Gillian Cannon sold 1,190 shares of Xenon Pharmaceuticals stock in a transaction dated Friday, June 5th. The stock was sold at an average price of $53.14, for a total value of $63,236.60. Following the completion of the transaction, the director directly owned 1,455 shares of the company's stock, valued at approximately $77,318.70. This represents a 44.99% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 2.91% of the company's stock.

Xenon Pharmaceuticals Price Performance

XENE opened at $64.55 on Friday. Xenon Pharmaceuticals Inc. has a one year low of $32.78 and a one year high of $72.66. The business has a 50 day simple moving average of $60.06 and a two-hundred day simple moving average of $54.14. The firm has a market capitalization of $6.24 billion, a price-to-earnings ratio of -13.73 and a beta of 0.62.

Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last posted its earnings results on Thursday, August 6th. The biopharmaceutical company reported ($1.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.16) by $0.05. During the same period in the previous year, the firm earned ($1.07) EPS. As a group, sell-side analysts expect that Xenon Pharmaceuticals Inc. will post -4.92 EPS for the current fiscal year.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company's research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon's scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company's pipeline comprises multiple preclinical and clinical programs.

Want to see what other hedge funds are holding XENE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source